TORONTO--(BUSINESS WIRE)--Highland Therapeutics Inc. (“Highland”), a pharmaceutical company, today announced that its wholly owned subsidiary, Ironshore Pharmaceuticals & Development, Inc. (“Ironshore”), will host a poster presentation highlighting Phase III clinical data at the upcoming American Psychiatric Association (APA) 168th Annual Meeting in Toronto, Canada.
“The APA meeting is one of the most well attended psychiatric medical conferences; attracting physicians from around the world. We are excited to be sharing clinical data we have generated to date with the medical community at this prestigious event,” said Dr. Randy Sallee, Ironshore’s Chief Medical Officer. “We will be participating at all of the major U.S. psychiatry conferences and expect to be active in 2015 with respect to publishing clinical data and market research findings in peer-reviewed medical journals.”
Details of Ironshore’s poster session is below:
Poster #: P6-009
Monday, May 18, 2015, 2:00pm EDT
A Phase III, 6-Week, Open-Label, Dose Optimization Study of HLD200 in Children with Attention-Deficit Hyperactivity Disorder
Presented by Mary Ann McDonnell, Ph.D.
Specific information about the data contained in the poster is embargoed until the start of the meeting.
Commenting on HLD-200, Dr. McDonnell said, “Stimulants have been the cornerstone of ADHD pharmacologic treatment for decades and physicians continue to confidently prescribe methylphenidate and amphetamine as first-line therapy for the majority of their child and adolescent patients. However, despite their effectiveness, a substantial unmet medical need persists, as many families struggle with inadequately controlled ADHD symptoms and the related functional impairments during the morning routine. Existing long-acting stimulant therapies cannot adequately address this “gap” in coverage since they are dosed in the morning and take time before significant clinical effect is observed. Ironshore’s formulations were specifically designed and developed to provide clinically meaningful control of ADHD symptoms during the morning routine and throughout the day.”
About Highland Therapeutics Inc.
Highland Therapeutics Inc. is a specialty pharmaceutical company that, through its wholly owned subsidiary Ironshore Pharmaceuticals & Development, Inc., is leveraging its proprietary technology, DELEXIS®, to optimize the delivery of previously approved drug products. The Company’s lead product candidates, HLD-200 and HLD-100, are novel formulations of the psychostimulants (methylphenidate and amphetamine, respectively) used to treat ADHD and are being developed to address a prevalent unmet medical need in the treatment of the disease – inadequate symptom control during the morning routine. Intended for nighttime dosing, DELEXIS® is designed to provide a consistent delay in the initial release of the active drug, followed by a period of extended release; with the objective of providing control of ADHD symptoms immediately upon wakening and throughout the day.
Highland Therapeutics Inc. is a client of MaRS Discovery District’s Health Venture Services group, which provides advisory services, connections to talent, customer & capital networks, and market intelligence to high-impact, Ontario-based life sciences ventures, helping them commercialize their ideas and build globally competitive companies.
For further information, please visit the Company’s website at www.highlandtherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking information, which reflects Highland’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Highland’s control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Highland assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
